Skip to main content
An official website of the United States government


Placeholder slot

This page contains brief information about daratumumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Daratumumab is approved to be used alone or with other drugs to treat:

Daratumumab is also available in a different form, combined with hyaluronidase. For more information, see the Drug Information Summary for Daratumumab and hyaluronidase-fihj.

Daratumumab is also being studied in the treatment of other types of cancer.

More About Daratumumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Daratumumab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Daratumumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: